BIAF

Business Context and Reporting Period

Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Bioaffinity develops noninvasive diagnostics for early-stage lung cancer using flow cytometry and AI-driven analysis. Its primary product is CyPath® Lung, a sputum-based test. In September 2023, the company acquired Precision Pathology Laboratory Services (PPLS), a CAP-accredited and CLIA-certified laboratory, to commercialize its tests. The company is classified as an Emerging Growth Company and a Smaller Reporting Company.

Key Financial Metrics

Revenue Breakdown (2024): Patient service fees ($8.2M), Histology service fees ($1.1M), Medical director fees ($67k), and DOD observational studies ($9k). CyPath® Lung testing revenue specifically reached approximately $0.5 million in 2024, a 1,400% increase from 2023.

Material Changes vs. Prior Period

• Revenue Growth: Consolidated revenue increased 270% to $9.4 million, driven primarily by the full-year inclusion of PPLS operations following its September 2023 acquisition.
• Expense Increase: Total operating expenses rose 74% to $18.3 million. Direct costs increased 244% and SG&A increased 46%, largely due to PPLS operating for the full fiscal year compared to only 3.5 months in 2023.
• Liquidity Decline: Cash and cash equivalents decreased by $1.7 million to $1.1 million. Net cash used in operating activities was $7.3 million.
• Financing Activity: The company raised approximately $6.9 million in gross proceeds from equity transactions in 2024, including registered direct offerings and warrant exercises.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Cost Reduction: In March 2025, the company announced strategic actions to achieve approximately $4 million in annual cost savings at PPLS by reducing labor costs and discontinuing low-margin pathology services to focus on CyPath® Lung.
• Clinical Trials: The company submitted a pivotal clinical trial protocol for FDA de novo classification (Class II IVD) in March 2025. Enrollment for the 3,200-patient trial is expected to begin in Q2 2025.
• Recent Financing: In February 2025, the company raised approximately $1.4 million through a warrant inducement agreement.

Risks and Contingencies

• Going Concern: The independent auditor has issued an opinion with an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern. Management estimates cash resources are sufficient only through April 2025 without additional funding.
• Regulatory Risk: CyPath® Lung is currently marketed as a Laboratory Developed Test (LDT). The FDA is phasing out enforcement discretion for LDTs; the company is pursuing FDA de novo classification to mitigate this risk.
• Nasdaq Compliance: The company received notice in February 2025 that its stock price fell below the $1.00 minimum bid price requirement. It has 180 days (until August 6, 2025) to regain compliance.

Investor Verification Checklist

• Cash Runway: Verify the company's ability to secure additional capital before April 2025 to avoid insolvency.
• Cost Cutting Execution: Monitor the implementation of the announced $4 million cost-saving measures and their impact on PPLS operations.
• Nasdaq Status: Track the stock price to ensure it meets the $1.00 minimum bid requirement for 10 consecutive days before August 2025 to avoid delisting.
• Regulatory Pathway: Confirm the timeline and progress of the pivotal clinical trial for FDA de novo classification.
• Revenue Quality: Assess the sustainability of revenue growth from PPLS, specifically the mix of high-margin CyPath® Lung tests versus lower-margin general pathology services.